文献速递乳腺癌

Buparlisib联合氟维司群对比安慰剂联合氟维司群治疗绝经后激素受体阳性HER2阴性晚期乳腺癌(BELLE-2):一项随机双盲安慰剂对照3期试验

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-05-30

BELLE-2是一项随机双盲安慰剂对照3期试验,纳入1147例绝经后激素受体阳性HER2阴性晚期乳腺癌患者,比较Buparlisib联合氟维司群与安慰剂联合氟维司群的疗效。总人群中Buparlisib组中位无进展生存期6.9个月 vs 安慰剂组5.0个月(HR 0.78,95%CI 0.67-0.89,单侧P=0.00021)。Buparlisib组3-4级不良事件以丙氨酸氨基转移酶升高(25% vs 1%)等为主,因毒性未进一步开展研究。

要点

  • 总人群中Buparlisib组中位PFS 6.9个月 vs 安慰剂组5.0个月(HR 0.78,95%CI 0.67-0.89)。
  • PI3K通路激活患者中Buparlisib组中位PFS 6.8个月 vs 安慰剂组4.0个月(HR 0.76,95%CI 0.60-0.97)。
  • Buparlisib组3-4级丙氨酸氨基转移酶升高146例(25%)vs 安慰剂组6例(1%)。

核心结论

  • PI3K抑制联合内分泌治疗在绝经后内分泌抵抗、激素受体阳性HER2阴性晚期乳腺癌中有效。
  • 需要使用更选择性的PI3K抑制剂(如α特异性PI3K抑制剂)以进一步改善该场景下的安全性和获益。
  • 由于该联合方案的毒性,未进一步开展研究。

研究设计与样本

  • BELLE-2为随机、双盲、安慰剂对照、多中心3期试验。
  • 纳入18岁及以上绝经后女性,组织学确诊激素受体阳性、HER2阴性不可手术局部晚期或转移性乳腺癌,芳香化酶抑制剂治疗中或治疗后进展,晚期阶段既往化疗不超过一线。
  • 2012年9月7日至2014年9月10日,来自29个国家267个中心的1147例患者按1:1随机分配至Buparlisib联合氟维司群组(n=576)或安慰剂联合氟维司群组(n=571)。
  • 随机按PI3K通路激活状态(激活 vs 非激活 vs 未知)和内脏疾病状态(有 vs 无)分层。
  • 主要终点为总人群、已知PI3K通路状态患者及PI3K通路激活患者中研究者评估的无进展生存期(RECIST 1.1)。

主要发现

  • 总人群(n=1147)中位无进展生存期Buparlisib组6.9个月(95%CI 6.8-7.8) vs 安慰剂组5.0个月(95%CI 4.0-5.2),HR 0.78(95%CI 0.67-0.89),单侧P=0.00021。
  • 已知PI3K状态患者(n=851)中位无进展生存期Buparlisib组6.8个月(95%CI 5.0-7.0) vs 安慰剂组4.5个月(95%CI 3.3-5.0),HR 0.80(95%CI 0.68-0.94),单侧P=0.0033。
  • PI3K通路激活患者(n=372)中位无进展生存期Buparlisib组6.8个月(95%CI 4.9-7.1) vs 安慰剂组4.0个月(95%CI 3.1-5.2),HR 0.76(95%CI 0.60-0.97),单侧P=0.014。
  • Buparlisib组 vs 安慰剂组最常见的3-4级不良事件:丙氨酸氨基转移酶升高146例(25%)/573例 vs 6例(1%)/570例;天冬氨酸氨基转移酶升高103例(18%) vs 16例(3%);高血糖88例(15%) vs 1例(<1%);皮疹45例(8%) vs 无。
  • Buparlisib组严重不良事件134例(23%)/573例 vs 安慰剂组90例(16%)/570例;最常见严重不良事件(≥2%患者)为丙氨酸氨基转移酶升高17例(3%)/573例 vs 1例(<1%)/570例和天冬氨酸氨基转移酶升高14例(2%) vs 1例(<1%);无治疗相关死亡。

临床怎么用

  • 作者认为PI3K抑制联合内分泌治疗在绝经后内分泌抵抗、激素受体阳性HER2阴性晚期乳腺癌中有效。
  • 作者认为需要使用更选择性的PI3K抑制剂(如α特异性PI3K抑制剂)以进一步改善该场景下的安全性和获益。
  • 作者指出由于该联合方案的毒性,未进一步开展研究。

局限性

  • 由于该联合方案的毒性,未进一步开展研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the PI3K pathway activation status as a biomarker for clinical benefit. METHODS: The BELLE-2 trial was a randomised, double-blind, placebo-controlled, multicentre study. Postmenopausal women aged 18 years or older with histologically confirmed, hormone receptor-positive and human epidermal growth factor (HER2)-negative inoperable locally advanced or metastatic breast cancer whose disease had progressed on or after aromatase inhibitor treatment and had received up to one previous line of chemotherapy for advanced disease were included. Eligible patients were randomly assigned (1:1) using interactive voice response technology (block size of 6) on day 15 of cycle 1 to receive oral buparlisib (100 mg/day) or matching placebo, starting on day 15 of cycle 1, plus intramuscular fulvestrant (500 mg) on days 1 and 15 of cycle 1, and on day 1 of subsequent 28-day cycles. Patients were assigned randomisation numbers with a validated interactive response technology; these numbers were linked to different treatment groups which in turn were linked to treatment numbers. PI3K status in tumour tissue was determined via central laboratory during a 14-day run-in phase. Randomisation was stratified by PI3K pathway activation status (activated vs non-activated vs and unknown) and visceral disease status (present vs absent). Patients, investigators, local radiologists, study team, and anyone involved in the study were masked to the identity of the treatment until unblinding. The primary endpoints were progression-free survival by local investigator assessment per Response Evaluation Criteria In Solid Tumors (version 1.1) in the total population, in patients with known (activated or non-activated) PI3K pathway status, and in PI3K pathway-activated patients. Efficacy analyses were done in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study drug and had at least one post-baseline safety assessment according to the treatment they received. This trial is registered with ClinicalTrials.gov, number NCT01610284, and is currently ongoing but not recruiting participants. FINDINGS: Between Sept 7, 2012, and Sept 10, 2014, 1147 patients from 267 centres in 29 countries were randomly assigned to receive buparlisib (n=576) or placebo plus fulvestrant (n=571). In the total patient population (n=1147), median progression-free survival was 6·9 months (95% CI 6·8-7·8) in the buparlisib group versus 5·0 months (4·0-5·2) in the placebo group (hazard ratio [HR] 0·78 [95% CI 0·67-0·89]; one-sided p=0·00021). In patients with known PI3K status (n=851), median progression-free survival was 6·8 months (95% CI 5·0-7·0) in the buparlisib group vs 4·5 months (3·3-5·0) in the placebo group (HR 0·80 [95% CI 0·68-0·94]; one-sided p=0·0033). In PI3K pathway-activated patients (n=372), median progression-free survival was 6·8 months (95% CI 4·9-7·1) in the buparlisib group versus 4·0 months (3·1-5·2) in the placebo group (HR 0·76 [0·60-0·97], one-sided p=0·014). The most common grade 3-4 adverse events in the buparlisib group versus the placebo group were increased alanine aminotransferase (146 [25%] of 573 patients vs six [1%] of 570), increased aspartate aminotransferase (103 [18%] vs 16 [3%]), hyperglycaemia (88 [15%] vs one [<1%]), and rash (45 [8%] vs none). Serious adverse events were reported in 134 (23%) of 573 patients in the buparlisib group compared with 90 [16%] of 570 patients in the placebo group; the most common serious adverse events (affecting ≥2% of patients) were increased alanine aminotransferase (17 [3%] of 573 vs one [<1%] of 570) and increased aspartate aminotransferase (14 [2%] vs one [<1%]). No treatment-related deaths occurred. INTERPRETATION: The results from this study show that PI3K inhibition combined with endocrine therapy is effective in postmenopausal women with endocrine-resistant, hormone receptor-positive and HER2-negative advanced breast cancer. Use of more selective PI3K inhibitors, such as α-specific PI3K inhibitor, is warranted to further improve safety and benefit in this setting. No further studies are being pursued because of the toxicity associated with this combination. FUNDING: Novartis Pharmaceuticals Corporation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017. PMID: 28576675. doi:10.1016/S1470-2045(17)30376-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。